ABSTRACT
F-waves result from the discharge of the motoneurons following their antidromic activation. The F-wave appears, as an indirect (the F-wave latency decreases when the stimulation site moves away from the muscular detection) and late response (occurring after the M response). In practice, the most useful parameter is the F-wave minimal latency, provided that at least seven distinct F-waves are evoked. When the analysis is relative either to the controlateral side, or to a former examination, this parameter is one of most sensitive in electroneuromyography. F-wave evocation implies conduction along the entire peripheral nervous system, and particularly its proximal part, which is not investigated by nervous trunks conduction velocity studies. Thus, F wave study is the most useful in plexopathies and polyradiculonevritis. In the early phase of Guillain-Barré syndrome, their absence may be the unique sign indicative of proximal conduction blocks.
Subject(s)
Action Potentials/physiology , Motor Neurons/physiology , Neural Conduction/physiology , Demyelinating Diseases/etiology , Demyelinating Diseases/physiopathology , Electric Stimulation/methods , Electrodiagnosis/methods , Electrophysiological Phenomena , Humans , Motor Neuron Disease/etiology , Motor Neuron Disease/physiopathology , Reflex/physiologyABSTRACT
The current Anglo-Saxon trend is to consider that schizophrenia includes all psychoses. However, far from being a uniform set, there is a lot of different clinical presentations of patients with psychosis. Chronic delusional psychosis, as a paradigm, show that subtyping psychosis on a clinical basis is useful for therapeutic and prognosis purposes.
Subject(s)
Delusions/psychology , Psychotic Disorders/psychology , Chronic Disease , Humans , Schizophrenia, Paranoid/psychologyABSTRACT
Depression and cardiovascular diseases represent a major public health problem worldwide. Recent studies have shown that depression is a risk factor for the development of coronary artery disease (CAD) in healthy people and also increases morbidity and mortality in depressed patients with CAD. Others studies have shown that selective serotonin inhibitors (SSRIs) constitute a safe and effective treatment for depressed patients with heart disease. There are also data suggesting that treating depression with SSRIs has a protective role in myocardial infarction and may improve outcomes, including mortality.
